8/8/2012 7:49:16 AM
Ranbaxy Laboratories may have forgone the launch of its generic version of blockbuster sleep disorder drug Provigil during a lucrative six-month marketing exclusivity period as part of its regulatory settlement with US authorities, say analysts who estimate that this might have cost the drugmaker $50-100 million in revenues. The Indian drugmaker had, earlier this year, forfeited marketing exclusivity for three drugs but it had not disclosed the identity of these drugs. Analysts say Provigil, which is used to treat daytime sleepiness and obstructive sleep apnea, is one of these three drugs.
comments powered by